F&P Healthcare sues ResMed
Recommendation
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
Fisher & Paykel Healthcare has filed a patent infringement case against larger competitor ResMed in the US District Court of California. The company alleges that some of ResMed's continuous positive airway pressure (CPAP) devices and accessories infringe patents held by F&P Healthcare, including the flagship AirSense 10 and AirCurve 10 range of flow generators, ClimateLineAir heated air tubes, and Swift masks.
‘Fisher & Paykel Healthcare is seeking all available remedies, including damages and injunctive relief', the announcement said.
It's too early to tell how this will play out and judging the financial repercussions – if any – is next to impossible at this stage. ResMed's management is yet to make an announcement but we will keep you updated as things progress.
In ResMed: Result 2016 from 29 Jul 16 (Hold – $9.06) we said ‘ResMed is getting close to our Sell price and is on our watch list for a potential downgrade. Given the price increase, the stock may have become a large portion of your portfolio. If that's the case, you should consider taking some chips off the table in favour of the better opportunities on our Buy list.' This patent infringement case doesn't give us any extra optimism – although it's important not to jump at shadows. For now, HOLD.
F&P Healthcare, on the other hand, is still trading above our estimate of intrinsic value with a forward price-earnings ratio of 35. That's expensive, especially relative to ResMed's forward price-earnings ratio of 24, and we're sticking with SELL.
Note: The Intelligent Investor Growth portfolio owns shares in ResMed. You can find out about investing directly in Intelligent Investor and InvestSMART portfolios by clicking here.
Disclosure: The author owns shares in ResMed.
Recommendation
Call 1300 880 160
Start a chat
Schedule a call
